Pancreatitis has several different causes that largely depend on the specific genetic and environmental risk factors involved and their interactions. The disease subtypes require markedly different approaches to management and involve different treatments and likely outcomes. PancreasDx® incorporates the following to give you tools to provide personalized care to your patients
PancreasDx® is a next-generation sequencing panel of 12 genes related to susceptibility to the different subtypes of chronic pancreatitis.
PancreasDx® incorporates genetic sequencing information, patient health records and environmental exposures to provide a personalized guide for patient management.
There is growing evidence that suggests that most diseases of the pancreas have a genetic predisposition or basis. Genetic testing can help you find the right treatment for your patient, giving valuable information into what treatments would be most effective to their unique genetic makeup.
Many forms of pancreatitis involve a genetic predisposition or basis. Genetic testing can help you find the right treatment for your patient’s specific genetic vulnerability. Discover insights into what treatments would be most effective and help your patients avoid unnecessary diagnostic procedures.
Frequently asked questions about PancreasDx®, Ariel and how you can use genetic information to improve outcomes for your patients.
Identifying the underlying biological causes of symptoms can help direct therapy and guide medical management specific to the patient’s disease process. For example, genetic conditions such as hereditary pancreatitis and cystic fibrosis can both increase the risk of pancreatitis, but involve different treatments and clinical considerations. Early detection of the cause or causes of the disease process may prevent extensive diagnostic evaluations, delayed diagnosis and more severe end-stage disease.
Genetic testing for pancreatitis is recommended for individuals with pancreatitis that meet one or more of the following criteria:
Additionally, individuals that meet any of the following criteria may also benefit from genetic testing:
Ariel’s test goes beyond genetics to incorporate genetic testing, patient medical and family history, patient biomarkers, and up-to-date management considerations to provide a comprehensive and actionable precision medicine report.
PancreasDx® tests for predisposition to both Mendelian (monogenic) and complex (multifactorial) forms of disease. A minority of pancreatitis patients have a monogenic cause of disease. Therefore, testing for predisposing risk variants in addition to monogenic disease variants assures a complete picture of known genetic predisposition.
PancreasDx® is a comprehensive next-generation sequencing panel of genes related to susceptibility to pancreatitis and related complications.
ArielDx® Lipid is a next-generation sequencing panel of genes related to genetic susceptibility to hypertriglyceridemia, a predisposing factor to pancreatitis. ArielDx®Lipid is available as an add-on to PancreasDx® during the ordering process.
Ariel is committed to a streamlined and convenient ordering and results disclosure process:
Ariel offers educational materials on pancreatitis, genetic testing, complex disease and other pertinent topics for clinicians and patients inside the portal. Patient counseling materials for use during informed consent discussions and test ordering are available.
Ariel also offers genetic counseling services for patients through an independent third-party genetic counseling provider over video or phone. Pre-test genetic counseling through a third party is included as an option with every test, which clinicians can request with every order. A request for post-test genetic counseling can be made through the Ariel provider portal. At that time, the patient’s contact information and PancreasDx® test results are provided to a third-party genetic counseling service. This third-party service will contact the patient to discuss cost and scheduling.
Yes. Ariel offers genetic counseling services for patients through an independent third-party genetic counseling provider over video or phone. Pre-test genetic counseling through a third-party is complimentary with every test, which clinicians can request with every order. A request for post-test genetic counseling can be made through the Ariel provider portal. At that time, the patient’s contact information and PancreasDx® test results are provided to a third-party genetic counseling service. This third party service will contact the patient to discuss cost and scheduling.
Mendelian, or monogenic, genetic variants are those traditionally associated with a high genetic risk for a disease or syndrome. Mendelian diseases for which pancreatitis is a feature include PRSS1-hereditary pancreatitis (autosomal dominant) and cystic fibrosis (autosomal recessive). However, Mendelian diseases are rare causes of pancreatitis. Instead, the etiology is typically complex. Multiple low-to-moderate impact risk variants have been associated with the development and progression of pancreatitis. Risk variants increase the risk for disease, but they are not considered to be causal in isolation. Instead, risk variants act in concert with other genetic and environmental influences. Pancreatitis research and clinical studies have shown that pancreatitis patients typically harbor several risk variants in combination with other environmental (e.g. tobacco, alcohol) or anatomic (e.g. pancreas divisum) risk factors.
Ariel reports both Mendelian and risk variants to provide a comprehensive picture of your patient’s genetic predisposition for pancreatitis and related complications. Although risk variants do not cause disease on their own, known associations with other variants, environmental or anatomic factors can provide insight into the etiology of a patient’s disease, thereby guiding future management strategies.
Ariel accepts all insurance plans. As a new provider, we are not considered an in-network provider with all insurance plans. While the organization continues to grow, Ariel will work towards establishing in-network status.
The Ariel team follows the process below:
Ariel is required by law to bill patients for applicable co-pays, co-insurance, and deductibles, as directed by their individual insurance beneﬁt plan. Ariel will partner with the patient to implement the most appropriate payback plan based on the individual’s financial need.
Depending on the patient’s insurance plan, there may be situations where Ariel is considered an out-of-network provider and the payment for our test will be sent to the patient directly. The patient is legally responsible for re-issuing that payment, with a copy of the Explanation of Beneﬁts, to Ariel for processing.
To ensure that Ariel services are accessible to medically necessary patients, several options are available to support any patient out-of-pocket costs remaining after all billing efforts are exhausted with the insurance plan. Available options include payment plans, prompt pay discounts, and ﬁnancial assistance, based on individual need.
Please tell your patient to expect an email from Ariel. Once you place an order in the secure portal, Ariel will send your patient a ‘Welcome’ email with a link to Ariel’s secure patient portal to register. The patient can then follow the instructions in their email to register in Ariel’s online portal, provide their insurance information and complete the informed consents and their patient profile. Once the requisite forms are compete, Ariel dispatches a DNA testing kit to the patient’s house. This kit also has all the necessary instructions for collecting the sample and shipping it back to Ariel.
The turnaround time for the test is approximately 4 to 6 weeks from the time the patient sample is received in our laboratory.